(Reuters) – Pfizer and French pharmaceutical peer Valneva announced on Thursday that a phase 2 study for its VLA15 Lyme disease vaccine candidate showed a “strong immune response” in both children and adolescents one month after receiving a booster shoot.
“The Phase 2 booster results emphasize the vaccine candidate’s potential to provide immunity against Lyme disease in paediatric and adolescent populations,” the two companies say in a statement.
(Reporting by Victor Goury-Laffont; Editing by Janane Venkatraman)
